Timing is Everything; Tempo Raises Series A

Now that Tempo has raised a $12.1 million Series A round from Polaris, Venrock, Lux Capital and former Biogen Idec Inc. Chairman William Rastetter, PhD, the company is on the way toward solving a tricky drug delivery problem

Polaris Venture Partners has done quite well with what might broadly be called pharmaceutical technologies—businesses based on drug delivery and reformulation, rather than discovery. Their secret weapon: the Massachusetts Institute of Technology and, in particular, researcher Robert Langer, ScD.

Now they’re turning the crank again, though this time Langer is merely a key MIT connection (and a board member).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business